Community-based family planning (CBFP) activities need the buy-in of government health officials and administrators, family planning program managers and providers, and the community. The Policy & Advocay section of the CBFP Toolkit includes resources on:
Advocacy to Policymakersto help address needed change in policies, guidelines, regulations and standard operating procedures that will help to foster effective implementation and scale-up of CBFP services.
Task Sharing, a viable option for CBFP programs to utilize for improving or expanding health care coverage to rural and underserved areas.
Family Planning Guidelines, for countries to refer to when developing, reviewing, or updating their own national family planning guidelinesto help programs and providers offer quality services that are free from unnecessary requirements and medical barriers.
Have a suggested resource or comment about this section? Please visit our discussion board.
In June 2009, a technical consultation held at the World Health Organization (WHO) in Geneva concluded that evidence supports the introduction, continuation, and scale-up of community-based provision of progestin-only injectable contraceptives. The group of 30 technical and programme experts reviewed scientific and programmatic experience, which largely focused on the progestin-only injectable, depot-medroxyprogesterone acetate (DMPA).
This online transparency provides a graphical representation of the potential contribution of community health workers to improved maternal and child health in many parts of the world.
A global consultation of programme managers, policy makers and experts was convened by the Alliance in April 2010 in Montreux, Switzerland, to review the recommendations of a systematic review on Community Health Workers (CHWs), share experiences, and develop broad agreement on key messages for countries to use to integrate CHWs into their national health workforce. Key messages were identified around the following three areas: the planning, production and deployment; attraction and retention; and performance management of CHW.
Injectable contraceptives are popular among women, especially in sub-Saharan Africa. Health officials and providers in a growing number of countries seek to make injectable contraceptives more widely available at the community level through trained paraprofessionals. Studies and field observations have found that community health workers (CHWs) can provide injectables safely and that community access to injectables attracts new contraceptive users.
A “champion” is a “charismatic advocate of a belief, practice, program, policy and/or technology.” It is a champion’s unique combination of skills—passion, persistence, and persuasiveness—that distinguish him or her from other advocates. A 2007 Cochrane review concluded that the use of opinion leaders can successfully promote evidence-based practices. Engaging influential opinion leaders can be an effective advocacy approach for advancing social, economic, political, or public health issues.
Participation of community health workers (CHWs) in the provision of primary health care has been experienced all over the world for several decades, and there is an amount of evidence showing that they can add significantly to the efforts of improving the health of the population, particularly in those settings with the highest shortage of motivated and capable health professionals.
Describes the key components of the approaches that The USAID | Health Policy Initiative/ Task Order 1 uses to assist national governments in countries such as Malawi and Rwanda to incorporate injectable contraceptives into CBD programs.
This toolkit aims to help those working in family planning across Africa to effectively advocate for renewed emphasis on family planning to enhance the visibility, availability, and quality of family planning services for increased contraceptive use and healthy timing and spacing of births, ultimately, improved quality of life across the region. It was developed in response to requests from several countries to assist them in accelerating their family planning advocacy efforts.
This kit provides information and tools with which decision-makers can advocate for and initiate community-based distribution (CBD) of the injectable contraceptive depot-medroxyprogesterone acetate (DMPA or Depo-Provera). Drawing on research and programs from Africa, Asia, and Latin America, the kit presents seven briefs with evidence supporting the safety and efficacy of CBD provision of DMPA. It discusses best practices for successful CBD of DMPA provision, such as training, counseling, and ensuring supply.
Family Health International (FHI) developed this package of eight briefs to present the benefits of long-acting and permanent methods (LAPMs) and the rationale for introducing or revitalizing them within national reproductive health and family planning programs. They are meant to inform policy-makers, program managers, and donors, as well as diverse stakeholders at the community level who wish to improve and expand LAPM provision within their communities.
This new report jointly published by The Alan Guttmacher Institute (AGI) and the United Nations Population Fund makes the case for increased funding for sexual and reproductive health services—particularly in resource-poor countries—by illustrating the unusually broad societal and individual impact of investments in sexual and reproductive health.
This training manual developed by the POLICY Project was prepared to help representatives of non-governmental organizations and other formal groups of civil society form and maintain advocacy networks and develop effective family planning/reproductive health advocacy skills. The manual's tools and approaches can be used to affect family planning and reproductive health policy decisions at the international, national, regional, and local levels. The manual is based on the principle that advocacy strategies and methods can be learned.
Advocacy is a strategy to influence policy makers when they make laws and regulations, distribute resources, and make other decisions that affect peoples' lives. The principal aims of advocacy are to create policies, reform policies, and ensure policies are implemented. There are a variety of advocacy strategies, such as discussing problems directly with policy makers, delivering messages through the media, or strengthening the ability of local organizations to advocate.
A three-day, six-session curriculum designed as a companion piece to Cairo, Beijing, and Beyond: A Handbook on Advocacy for Women Leaders. This manual uses participatory methodologies and is based on CEDPA's experience in building the skills of non-governmental organization leaders to advocate for change in the reproductive health arena. While the background information and role play scenarios deal directly with reproductive health issues, a trainer can adapt the sessions for other contexts.
The Integrated Family Health Program (IFHP) is a five-year USAID-funded program to promote an integrated model for strengthening maternal and child health, family planning (FP), and reproductive health services for rural and underserved populations in Ethiopia. Led by Pathfinder International and John Snow, Inc. in partnership with the Consortium of Reproductive Health Associations, IFHP has pursued scale-up of community-based provision of Implanon since 2009.
The specific objectives of the study were to assess client satisfaction and competence of community-based providers in providing the three-monthly injectable contraceptive depot-medroxyprogesterone acetate (DMPA).
Based on a review of the literature and country examples, the brief describes why task shifting is important and highlights some key steps in planning for, developing and supporting cadres involved in task shifting.
The World Health Organization (WHO) has issued and periodically updates global technical guidelines that cover how to provide contraceptive methods and to whom. National family planning and reproductive health programs can use the WHO global recommendations and other resources with international guidance as a basis for developing, reviewing, or updating their own national family planning guidelines.
This document reviews the medical eligibility criteria for use of contraception, offering guidance on the safety of use of different methods for women and men with specific characteristics or known medical conditions. The recommendations are based on systematic reviews of available clinical and epidemiological research. It is a companion guideline to Selected practice recommendations for contraceptive use.
This guide provides guidance on how to provide contraceptives, with the goals of maximizing effectiveness and managing side effects and other problems. The second edition contains 33 recommendations ranging from when to start a method, how to manage problems women experience using certain methods, how to provide emergency contraception, and what clinical exams to perform before a method can be initiated.
The WHO Model Lists of Essential Medicines has been updated every two years since 1977. The current version, the 15th list, dates from March 2009.
Click here for additional languages and editions.
This handbook offers clinic-based health care professionals in developing countries the latest guidance on providing contraceptive methods. Through an organized, collaborative process, experts from around the world have come to consensus on this practical guidance that reflects the best available scientific evidence. The World Health Organization (WHO) convened this process. Many major technical assistance and professional organizations have endorsed and adopted this guidance.
The World Health Organization (WHO) develops detailed criteria that health care workers can follow to determine which contraceptive methods are medically suitable for their clients. These criteria are based on the most current scientific knowledge about the effectiveness, risks, and benefits of various family planning methods, and they can help providers guide their clients in making safe and informed decisions. The WHO recently revised the criteria in response to recommendations made by an expert working group who met in Geneva, Switzerland, in April 2008.
On 1–4 April 2008, WHO convened an expert Working Group in Geneva, Switzerland, to revise the second edition in response to newly published evidence and requests for clarification of specific recommendations from users of the guideline. This document summarizes the changes made to recommendations related to questions 6, 9, 11, 18 and 22 in the second edition of the Selected practice recommendations for contraceptive use. The revised recommendations will appear in the 3rd edition of the guideline when it is published.
A job aid, the MEC wheel, was developed in collaboration with the INFO project at John Hopkins University, the Communication Partnership for Family Health in Jordan, and the University of Ghana Medical School. This easy-to-use job aid will help providers to quickly identify Medical Eligibility Criteria relevant to their clients. The job aid was field-tested in three countries and found to be very useful to providers.
Produced by the Ministry of Public Health and Sanitation’s Division of Reproductive Health in collaboration with a number of organizations and institutions, this updated edition of the Kenya family planning guidelines incorporates the 2009 Medical Eligibility Criteria (MEC) from the World Health Organization (WHO).
These PowerPoint slides identify guideline components and leads the reader through the best practices for development, update, and dissemination of national guidelines.
WHO Upholds Guidance: Women With or at Risk of HIV Can Safely Use Hormonal Methods
WHO released a statement on February 16, 2012, upholding guidance indicating that women with HIV or at high risk of HIV can safely use hormonal contraceptives, including injectables, to prevent pregnancy. However, WHO is instructing health care providers to strongly advise such women who decide to use progestin-only injectables to also always use male or female condoms for protection against HIV. Read more about WHO's statement.